Corbus Pharmaceuticals Announces Presentation of Data from its Phase 2b Study in Cystic Fibrosis at NACFC 2020 As previously reported, lenabasum did not meet its primary efficacy endpoint in the studyLenabasum was well tolerated with no new safety findingsExploratory post-hoc analyses revealed unexpectedly low...

Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Topline data on schedule for Q3 2020Reduction in pulmonary exacerbations (PEx) as primary endpoint Study enrolled 426 participants regardless of CFTR mutation or background CFTR-targeting...